Investigational bispecific antibodies for the treatment of rheumatoid arthritis

Aliki I. Venetsanopoulou,Paraskevi V. Voulgari,Alexandros A. Drosos
DOI: https://doi.org/10.1080/13543784.2024.2351507
2024-05-09
Expert Opinion on Investigational Drugs
Abstract:Introduction Rheumatoid arthritis (RA) is an autoimmune disorder with a characteristic chronic inflammation of the synovium that may lead to the destruction of the joints in untreated patients. Interestingly, despite the availability of several effective treatments, many patients do not achieve remission or low disease activity or may experience disease relapse. Following the above unmet needs, bispecific antibodies (BsAbs) have emerged as a new approach to improve the disease's treatment. BsAbs are designed to simultaneously target two different proteins involved in RA pathogenesis, leading to enhanced efficacy and reduced side effects compared to traditional monoclonal antibodies (mAbs).
pharmacology & pharmacy
What problem does this paper attempt to address?